首页    期刊浏览 2024年11月07日 星期四
登录注册

文章基本信息

  • 标题:The frequency and availability of population-specific patient reported outcome measures and minimal clinically important differences among approved drugs in Canada
  • 作者:Allison Soprovich ; Allison Soprovich ; Meghan Ingstrup
  • 期刊名称:Health and Quality of Life Outcomes
  • 印刷版ISSN:1477-7525
  • 电子版ISSN:1477-7525
  • 出版年度:2019
  • 卷号:17
  • 期号:1
  • 页码:4
  • DOI:10.1186/s12955-018-1070-0
  • 语种:English
  • 出版社:BioMed Central
  • 摘要:Patient reported outcome measures (PROMs) and minimal clinically important differences (MCIDs) are included in Canada’s Common Drug Review (CDR) process to approve new drugs. Often, the measures report on the health-related quality of life (HRQoL), but can also describe the symptoms, efficacy and harms important to patients. They can be generic or population/condition specific, validated or not. We examined the frequency, availability and accessibility of validated, specific PROMs and MCIDs reported in the CDR reports. We searched the Canadian Agency for Drugs and Technologies in Health (CADTH) on-line database for completed Common Drug Review, Clinical Review Reports (CDR-CRR) between November 2013 and February 2017. Two independent reviewers examined the reports and references for PROMs and MCIDs. Both reviewers separately categorized the PROMs and MICDs according to purpose, validation, availability and funding received. Discrepancies were rectified by consensus with a third investigator. One-hundred and five unique PROMs were extracted from 39 CDR-CRR, 57% with a HRQoL component. 91/105 (87%) referenced a validation study and 62/105 (59%) referenced a validation study in the study population of interest. Fifty-seven MCID references were extracted from 39 CDR-CRR. 34/57 (60%) were specific to the study population of interest, and 36% had a HRQoL component. 50% of PROM and 53% of MCID references were publicly available. PROMs and MCIDs referenced in CDR-CRR show similar trends. The majority are validated, but not necessarily in the study population of interest. Continued critical examination is required to evaluate new drugs specific to the population of interest.
  • 关键词:Patient reported outcome measures ; Minimal clinically important difference ; Health technology assessment ; Transparency
Loading...
联系我们|关于我们|网站声明
国家哲学社会科学文献中心版权所有